
## NCTN Endocrine/Neuroendocrine Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



## NCTN Endocrine/Neuroendocrine Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor
A021901	II	Positive Bronchial Neuroendocrine Tumors
		A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab
		(REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical
A092204	II	Cancer
		NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in
CCTG-NE1	II	Metastatic/Unresectable Midgut NET
		Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab
		(NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine
S2012	11/111	Carcinomas (NEC)
		Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus
S2104	II	Observation in High-Risk Pancreatic Neuroendocrine Tumors